Safety, tolerability, and efficacy of orally administered cannabinoids in MS

Neurology

Volumn 58, Issue 9, 2002, Pages 1404-1407

  Killestein, J ^a   Hoogervorst, E L J ^a   Reif, M ^a   Kalkers, N F ^a   Van Loenen, A C ^a   Staats, P G M ^a   Gorter, R W ^a   Uitdehaag, B M J ^a   Polman, C H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; CANNABIS; DRONABINOL; PLACEBO;

ADULT; ARTICLE; ATAXIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; SPASTICITY; VERTIGO; XEROSTOMIA;

EID: 0037076468     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.58.9.1404     Document Type: Article

References (10)

1. Cannabinoids control spasticity and tremor in a multiple sclerosis model
2. Treatment of human spasticity with delta 9-Tetrahydrocannabinol
3. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis
4. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers
5. Preliminary trial of carisoprodol in multiple sclerosis
6. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force
7. A health-related quality of life questionnaire for multiple sclerosis patients
8. Endocannabinoids and multiple sclerosis: A blessing from the "inner bliss"?